OTTAWA, ON – Johnson & Johnson’s first 300,000 doses of the COVID-19 vaccine distribution plan in Canada next week was suspended after Health Canada learned that part of They’re manufactured in a Maryland facility that messes up the ingredients in 15 million doses. For the US market
The Emergency Biosolutions facility in Baltimore was recently cited by the U.S. Food and Drug Administration as violations, including failure to clean and sterilize, the potential for cross-contamination and Failure to follow the specified protocol.
The FDA orders factories to stop making additional J&J vaccines until the problem is resolved and an earlier dose error resulted in the destruction of all 15 million.
Health Canada has cleared the vaccine. 1.5 million doses of Oxford-AstraZeneca already produced in the factory. But I don’t think Canada’s J&J volume has any connection with the plant.
Now Health Canada said the pharmaceuticals that were actually part of the J&J vaccine were actually made there and sent elsewhere to complete the vaccine.
Health Canada said it was seeking information from the FDA and J & J’s pharmaceutical agency Janssen to determine if the 300,000 doses sent to Canada meet the required safety standards.
Until now, the J&J vaccine has not been used in Canada.
The volume arrived in Canada on Wednesday.
Follow The Gleaner on Twitter and Instagram @JamaicaGleaner and on Facebook @GleanerJamaica. Message us on WhatsApp at 1-876-499-0169. Or email us at email@example.com or firstname.lastname@example.org.